DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Loeys-Dietz syndrome — screening already-approved drugs against its 16-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLoeys-Dietz syndrome maps to a 16-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for loeys-dietz syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
transforming growth factor beta receptor 2 (TGFBR2) — TGFBR2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 6-methoxypyridin-3-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5QIN · 1.57 Å · ligand N-{4-[3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide (J2V). Experimental structure, not a prediction.
What the evidence adds up to
Loeys-Dietz syndrome is an autosomal dominant connective tissue disorder caused by heterozygous mutations in the genes encoding type I or type II transforming growth factor-beta receptor, and also by mutations in TGFB2 or SMAD3. The syndrome manifests with aggressive vascular pathology. Aneurysms may form at a young age and have a propensity for arterial dissection, and they rupture at diameters smaller than those used to dictate surgical intervention for other syndromes and disorders. One case report describes a 27-year-old woman with Loeys-Dietz syndrome who showed ectopic arterial enlargement over a 10-year period, with computed tomography changes and pathology findings documented at surgery. Another case report describes the anaesthetic management of a patient with type I Loeys-Dietz syndrome, the most common type accounting for more than 75% of cases, who presented for laparotomy.
The 2007 review states that early diagnosis and rapid intervention are instrumental in averting catastrophic events, and that serial imaging assessment by radiologists is an important component of management. The 2014 case report provides no outcome data beyond the anaesthetic management for a single laparotomy. The 2022 case report describes the 10-year surgical course of one patient but gives no quantitative survival or response data.
No drug treatment is mentioned in any of these abstracts. There is no evidence from controlled trials, no randomised data, and no pharmacological intervention tested. What is missing is any trial of a drug therapy, any patient stratification beyond the genetic subtypes, and any funding for a clinical study of a repurposed agent in Loeys-Dietz syndrome.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Roentgenology · 2007 · 84 citations
Loeys-Dietz Syndrome: MDCT Angiography Findings
AbstractOBJECTIVE: Loeys-Dietz syndrome is a newly described phenotype caused by heterozygous mutations in the genes encoding type I or II transforming growth factor-beta (TGF-beta) receptor. Characterized by a unique constellation of clinical and pathologic findings, Loeys-Dietz syndrome manifests with aggressive vascular pathology. Aneurysms may form at a young age and have a propensity for arterial dissection. In addition, aneurysms rupture at diameters smaller than those used to dictate surgical intervention for other syndromes and disorders. This article presents the spectrum of arterial pathology that may be identified on MDCT angiography in patients with Loeys-Dietz syndrome. CONCLUSION: For patients with Loeys-Dietz syndrome, early diagnosis and rapid intervention are instrumental in averting catastrophic events. Serial imaging assessment by radiologists is an important component in the management of these patients.
Journal of Evolution of Medical and Dental Sciences · 2014 · 0 citations · open access
ANAESTHETIC MANAGEMENT FOR A RARE CASE OF LOEYS - DIETZ SYNDROME FOR LAPAROTOMY
AbstractLoeys-Dietz syndrome (LDS) is an autosomally dominant connective tissue disorder characterised by vascular and skeletal manifestations. It is caused by mutations in the TGFBR1, TGFBR2, TGFB2 or SMAD3 genes. There are four types of which type I is the most common accounting for more than 75% of the cases. Here we report the anaesthetic management of a case of LDS type I who presented with abdominal pain with suspected twisted ovarian cyst for laparotomy.
Research Square · 2022 · 0 citations · open access
Ectopic Vasodilation of a young woman with Loeys-Dietz syndrome in 10 years
AbstractAbstract We report the 10-year surgical course of a 27-year-old young woman who underwent two surgeries s after being diagnosed with Loeys-Dietz syndrome (LDS). As previously reported, this case showed ectopic arterial enlargement, and we can follow its temporal changes over a 10-year period. We described computed tomography (CT) changes over time and the appearance and pathology findings in surgery.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
